ECSP14005917A - Preparaciones que comprenden emodépsido amorfo - Google Patents

Preparaciones que comprenden emodépsido amorfo

Info

Publication number
ECSP14005917A
ECSP14005917A ECIEPI20145917A ECPI201405917A ECSP14005917A EC SP14005917 A ECSP14005917 A EC SP14005917A EC IEPI20145917 A ECIEPI20145917 A EC IEPI20145917A EC PI201405917 A ECPI201405917 A EC PI201405917A EC SP14005917 A ECSP14005917 A EC SP14005917A
Authority
EC
Ecuador
Prior art keywords
including amorphous
preparations including
preparations
emodepside
amorphous emodepside
Prior art date
Application number
ECIEPI20145917A
Other languages
English (en)
Inventor
Peter Kleinebudde
Venkata-Rangarao Kanikanti
Petra Lange
Hans-Jürgen Hamann
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358491&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14005917(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of ECSP14005917A publication Critical patent/ECSP14005917A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Abstract

La invención se refiere a preparaciones que comprenden emodépsido amorfo en una matriz de polivinilpirrolidona, a productos farmacéuticos que comprenden tales preparaciones y a su uso contra endoparásitos en animales o seres humanos.
ECIEPI20145917A 2011-12-21 2014-06-19 Preparaciones que comprenden emodépsido amorfo ECSP14005917A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11194878 2011-12-21

Publications (1)

Publication Number Publication Date
ECSP14005917A true ECSP14005917A (es) 2015-12-31

Family

ID=47358491

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20145917A ECSP14005917A (es) 2011-12-21 2014-06-19 Preparaciones que comprenden emodépsido amorfo

Country Status (24)

Country Link
US (3) US9539331B2 (es)
EP (1) EP2793861B1 (es)
JP (1) JP6185930B2 (es)
KR (2) KR101978620B1 (es)
CN (2) CN108187028A (es)
AU (2) AU2012357848C1 (es)
BR (1) BR112014014973A2 (es)
CA (1) CA2859787C (es)
CL (1) CL2014001637A1 (es)
CO (1) CO6990713A2 (es)
CR (1) CR20140293A (es)
DO (1) DOP2014000140A (es)
EC (1) ECSP14005917A (es)
ES (1) ES2734352T3 (es)
HK (1) HK1255536A1 (es)
IL (1) IL233183B (es)
MX (2) MX368209B (es)
MY (1) MY175307A (es)
NI (1) NI201400065A (es)
PH (2) PH12014501438B1 (es)
RU (2) RU2651761C2 (es)
UA (1) UA115232C2 (es)
WO (1) WO2013092558A1 (es)
ZA (1) ZA201404529B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368209B (es) 2011-12-21 2019-09-24 Bayer Pharma Ag Star Preparaciones que comprenden emodepsido amorfo.
SG10202103403SA (en) 2015-05-20 2021-05-28 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic depsipeptide compounds
CN108699052B (zh) 2015-12-28 2022-04-29 勃林格殷格翰动物保健美国公司 驱虫缩酚酸肽化合物
CA3044038A1 (en) 2016-11-16 2018-05-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds
CN114195732A (zh) * 2022-01-04 2022-03-18 丽珠集团福州福兴医药有限公司 一种艾默德斯的单晶型iii及其制备方法
CN115444927B (zh) * 2022-09-19 2023-06-02 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 艾默德斯在制备治疗三阴性乳腺癌的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE211466T1 (de) * 1992-03-17 2002-01-15 Fujisawa Pharmaceutical Co Depsipeptide, herstellung und anwendung
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10031044A1 (de) 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
RU2315614C1 (ru) * 2006-04-19 2008-01-27 Бийтемир Ахмедович Султанбеков Средство "грепол" и способ применения его при паразитарных заболеваниях
RU2425825C2 (ru) * 2007-02-09 2011-08-10 Пфайзер Лимитед Амидоацетонитрильные производные, содержащие их фармацевтические композиции и их применение в изготовлении лекарственного средства
DE102008022520A1 (de) 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
EP2355802A1 (de) * 2008-11-14 2011-08-17 Ratiopharm GmbH Intermediate und orale darreichungsformen enthaltend lenalidomid
DE102009012423A1 (de) * 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
MX368209B (es) 2011-12-21 2019-09-24 Bayer Pharma Ag Star Preparaciones que comprenden emodepsido amorfo.

Also Published As

Publication number Publication date
MX368209B (es) 2019-09-24
MX2014007224A (es) 2014-09-22
KR20180084141A (ko) 2018-07-24
JP6185930B2 (ja) 2017-08-23
NI201400065A (es) 2015-12-10
KR101978620B1 (ko) 2019-08-28
NZ625817A (en) 2016-08-26
US10251932B2 (en) 2019-04-09
MX356094B (es) 2018-05-14
AU2012357848B2 (en) 2018-01-04
KR20140107296A (ko) 2014-09-04
UA115232C2 (uk) 2017-10-10
CR20140293A (es) 2014-07-14
CO6990713A2 (es) 2014-07-10
HK1255536A1 (zh) 2019-08-23
CN104023710A (zh) 2014-09-03
EP2793861B1 (de) 2019-05-01
DOP2014000140A (es) 2014-07-31
RU2018105003A (ru) 2019-02-22
ES2734352T3 (es) 2019-12-05
US20170182118A1 (en) 2017-06-29
CA2859787A1 (en) 2013-06-27
AU2018202376B2 (en) 2019-06-20
PH12018500368A1 (en) 2018-07-23
US20180153957A1 (en) 2018-06-07
RU2018105003A3 (es) 2021-06-11
US9539331B2 (en) 2017-01-10
WO2013092558A1 (de) 2013-06-27
PH12014501438A1 (en) 2014-10-08
AU2012357848A1 (en) 2014-07-10
CA2859787C (en) 2020-09-08
IL233183A0 (en) 2014-07-31
RU2761529C2 (ru) 2021-12-09
JP2015502377A (ja) 2015-01-22
MY175307A (en) 2020-06-18
US20140371139A1 (en) 2014-12-18
CN108187028A (zh) 2018-06-22
BR112014014973A2 (pt) 2017-06-13
RU2014129620A (ru) 2016-02-10
RU2651761C2 (ru) 2018-04-23
AU2012357848C1 (en) 2018-07-19
AU2018202376A1 (en) 2018-04-26
EP2793861A1 (de) 2014-10-29
IL233183B (en) 2020-01-30
PH12014501438B1 (en) 2014-10-08
KR101979049B1 (ko) 2019-05-15
ZA201404529B (en) 2017-06-28
CL2014001637A1 (es) 2014-11-21

Similar Documents

Publication Publication Date Title
NI201400065A (es) Preparaciones que comprenden emodépsido amorfo
CL2014000467A1 (es) Formulación que comprende cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas derivados; metodo para obtener sustancia efectiva como plaguicida derivada de la formulación antes indicada.
CL2014002258A1 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112015000534A2 (pt) método para a preparação de 2,4-dihidroxibutirato, microrganismo, organismo e uso
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CL2014002282A1 (es) Anticuerpos contra la metaloproteinasa de la matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que la contiene; y sus usos.
BR112012005389A2 (pt) preparações pesticidas
CL2014003472A1 (es) Pro-farmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilamida; composicion farmaceutica que los comprende; y su uso para tratar una infeccion bacteriana.
EA201391212A1 (ru) Новые применения хлорида холина в агрохимических препаратах
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
BRPI1015941A2 (pt) formulações de comprimido de 3-cianoquinolina e uso das mesmas.
GB201215159D0 (en) Composition
IT1398268B1 (it) Glicerosomi e loro impiego in preparazioni farmaceutiche e cosmetiche per uso topico
JP2013541099A5 (es)
CL2013001128A1 (es) Composicion que comprende penflufeno y oxido de cobre y/o tiabendazol; y su uso para proteger la madera frente a basidiomicetos.
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
BR112013019687A2 (pt) antraquinona contendo preparações/formulações de lignina.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
CL2013001853A1 (es) Bacteria no patogena gram negativa perteneciente a la clase betaproteobacteria y subfamilia neisseriaceae; extracto que la comprende; composicion que comprende a la bacteria o al extracto; y su uso para tratar o prevenir trastornos inflamatorios dermatologicos.
CR10457A (es) Vacuna contra los organismos como rickettsia
BR112013019924A2 (pt) composições para cuidado oral
CU20130041A7 (es) Micobacteria recombinante como vacuna contra la tuberculosis para uso en humanos